Form 4: Elanco EVP Modi Boosts Stake with New Equity Awards

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, reported significant acquisitions of common stock, restricted stock units, stock options, and deferred stock units.

Summary

• Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc., reported multiple transactions on March 1, 2026.
• Acquired 41,690 shares of common stock at a price of $0, increasing beneficial ownership to 165,463 shares, which included 691 shares from the Employee Stock Purchase Plan on January 31, 2026.
• Disposed of 19,375 shares of common stock at $26.4 per share, reducing beneficial ownership to 146,088 shares (likely for tax withholding related to vesting).
• Received a grant of 14,205 restricted stock units at a price of $0, bringing beneficial ownership to 160,293 shares.
• Acquired 29,025 employee stock options with an exercise price of $26.4 and a price of $0.
• Acquired 2,532 deferred stock units (match) at a price of $0.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued executive commitment through significant equity grants, which aligns management incentives with long-term company performance. The disposition is likely tax-related and not indicative of negative sentiment.

Positives

• Significant equity grants to a key executive, Rajeev A. Modi, align his interests with long-term shareholder value.
• The acquisition of 41,690 shares of common stock at $0, including shares from the Employee Stock Purchase Plan, demonstrates continued participation in company equity programs.
• The grant of 14,205 restricted stock units and 29,025 employee stock options at $0 further increases the executive's stake in the company's future performance.

Negatives

• The disposition of 19,375 shares at $26.4, while likely for tax purposes, represents a reduction in direct common stock holdings at that specific point.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend through March 1, 2029, and deferred stock units vest by December 31, 2027, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that significant equity grants to top executives like Rajeev A. Modi are a common practice in the animal health industry, aiming to incentivize long-term performance and align management's interests with shareholder returns. These grants typically reflect confidence in the company's future prospects and are a standard component of executive compensation packages designed to retain key talent.

Stakeholder Impact

• Shareholders: The increased equity stake of a key executive aligns management's financial interests with shareholder value creation over the long term.
• Employees: The Employee Stock Purchase Plan participation indicates broader employee engagement in company ownership.

Next Steps

• Vesting of restricted stock units: one-third on March 1, 2027, one-third on March 1, 2028, and the remaining one-third on March 1, 2029.
• Vesting of employee stock options: one-third on March 1, 2027, one-third on March 1, 2028, and the remaining one-third on March 1, 2029.
• Vesting of deferred stock units on December 31, 2027, with settlement upon termination of employment or in accordance with the Executive Deferral and Stock Match Plan.

Key Dates

Recommendation

The filing details routine executive compensation in the form of equity grants and a tax-related disposition. While these transactions increase the executive's long-term stake, they do not represent open market purchases or sales based on new material information that would warrant a 'buy' or 'sell' recommendation. The activity is expected and aligns with standard corporate governance and compensation practices, suggesting a 'hold' position for investors awaiting more substantive operational or financial news.

Keywords

Elanco Animal Health, ELAN, Insider Trading, Form 4, Equity Awards, Stock Options, Restricted Stock Units, Deferred Stock Units, Executive Compensation